The dosing suspension comes on the heels of a layoff announcement. In June, the Swiss company revealed its plan to cut 8,000 jobs with the goal to save $1 billion. And just earlier this week, the company revealed that up to half of the 1,400 jobs cuts in Switzerland will be leadership positions.
https://www.fiercebiotech.com/biotech/novartis-suspends-dosing-phase-2b-huntingtons-disease-trial-after-side-effects-reported